The discovery of immune checkpoint (IC) inhibitors in the treatment of other solid tumors such as anti-PD-1 and anti-CTLA-4 for non-small cell lung cancer and melanoma has drastically changed therapeutic management in those diseases achieving as high as 20-30% 5-year survival rates (5, 6). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.